Patents by Inventor Steven Morgan Lewis

Steven Morgan Lewis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10562982
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: February 18, 2020
    Assignees: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Stephen J Demarest, Xiufeng Wu, Raheleh Toughiri, Brian Arthur Kuhlman, Steven Morgan Lewis
  • Publication number: 20190211115
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH/CL) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Application
    Filed: March 11, 2019
    Publication date: July 11, 2019
    Inventors: Stephen J. Demarest, Xiufeng Wu, Raheleh Toughiri, Brian Arthur Kuhlman, Steven Morgan Lewis
  • Patent number: 10294307
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Grant
    Filed: July 6, 2018
    Date of Patent: May 21, 2019
    Assignees: Eli Lilly and Company, The University of North Carolina at Chapel Hill
    Inventors: Stephen J Demarest, Xiufeng Wu, Raheleh Toughiri, Brian Arthur Kuhlman, Steven Morgan Lewis
  • Publication number: 20180305466
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain light-chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL) domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Application
    Filed: July 6, 2018
    Publication date: October 25, 2018
    Inventors: Stephen J Demarest, Xiufeng Wu, Raheleh Toughiri, Brian Arthur Kuhlman, Steven Morgan Lewis
  • Patent number: 10047167
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: August 14, 2018
    Assignees: Eli Lilly and Company, University of North Carolina at Chapel Hill
    Inventors: Stephen J Demarest, Xiufeng Wu, Brian Arthur Kuhlman, Steven Morgan Lewis, Raheleh Toughiri
  • Publication number: 20160039947
    Abstract: The present invention provides methods for producing Fabs and bi-specific antibodies comprising designed residues in the interfaces of the heavy chain-light chain variable (VH/VL) domain and the heavy chain-light chain constant (CH1/CL] domain, Fabs and bi-specific antibodies produced according to said processes and host cells encoding the same.
    Type: Application
    Filed: March 12, 2014
    Publication date: February 11, 2016
    Inventors: Stephen J Demarest, Xiufeng Wu, Brian Arthur Kuhlman, Steven Morgan Lewis, Raheleh Toughiri